ArticleAnatolian journal of cardiology2026
Vericiguat Alleviates Atrial Electrical and Structural Remodeling in Rats with Atrial Fibrillation.
Article in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe initiation and maintenance of atrial fibrillation (AF) are predominantly driven by progressive atrial structural remodeling, characterized by fibrosis and electrical conduction abnormalities. While vericiguat has shown efficacy in attenuating cardiac remodeling in heart failure (HF), its impact on AF remains insufficiently characterized.
methodsThis study investigated the cardioprotective effects of vericiguat in a Sprague-Dawley rat model of AF. Twenty-four male SD rats (250-300 g, 8-10 weeks old) were randomly assigned to control, AF, and vericiguat-treated groups. Echocardiography and histological assessments were performed, along with quantification of NT-proBNP, Collagen I, CaMKII, Cx43, ATG7, P62, and LC3II/I in the left atrium.
resultsCompared to controls, AF rats exhibited atrial enlargement, elevated myocardial fibrosis, and significant alterations in molecular markers. Vericiguat treatment effectively reversed these pathological changes. Specifically, NT-proBNP, Collagen I, CaMKII, ATG7, and LC3II/I were upregulated, while Cx43 and P62 were downregulated in the AF group-changes that were mitigated by vericiguat.
conclusionCollectively, these findings suggest that vericiguat attenuates atrial remodeling and AF progression by modulating autophagy and suppressing fibrosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.